论文部分内容阅读
目的探讨P-糖蛋白(P-gp)、谷胱苷肽S转移酶(GST-π)、拓扑异构酶Ⅱ(TOPOⅡ) 在卵巢上皮性肿瘤中的表达及意义。方法应用组织微阵列技术和免疫组织化学Elivision法,检测 104例卵巢上皮性肿瘤组织中P-gp、GST-π、TOPOⅡ的耐药性表达。结果在59例卵巢癌中,P-gp、 GST-π、TOPOⅡ的耐药性表达率分别为61．02％(36／59)、49．15％(29／59)、72．88％(43／59);P-gp与 GST-π、P-gp与TOPOⅡ、GST-π与TOPOⅡ及P-gp、GST-π与TOPOⅡ的耐药共表达阳性率分别为 40．67％(24／59)、37．28％(22／59)、32．20％(19／59)、25．42％(15／59);绝经后卵巢癌GST-π的耐药表达(60．52％)高于绝经前患者(33．33％,P=0．045);分化高(G1～G2)卵巢癌TOPOⅡ的耐药表达 (80．85％)高于分化低者(G3)(50．00％,P=0．028);病情进展组P-gp耐药表达明显高于无进展组(P =0．027);P-gp、GST-π、TOPOⅡ的耐药性表达与卵巢癌组织类型、手术病理分期、腹水细胞学及有无淋巴结转移无关。结论应用免疫组织化学方法联合检测卵巢癌中P-gp、GST-π、TOPOⅡ的耐药性表达,对于临床化疗敏感性的预测有一定提示,对预后的判断可能提供有价值的参考。
Objective To investigate the expression and significance of P-gp, GST-π, and TOPOII in epithelial ovarian neoplasms. Methods The expression of P-gp, GST-π and TOPO II in 104 epithelial ovarian tumors was detected by tissue microarray and immunohistochemical Elivision. Results In 59 cases of ovarian cancer, the expression rates of P-gp, GST-π and TOPO II were 61.02% (36/59), 49.15% (29/59), 72.88% ( 43/59); P-gp and GST-π, P-gp and TOPOII, GST-π and TOPOII and P-gp, GST-π and TOPO II co-expression rates were 40.67% (24/ 59), 37.28% (22/59), 32.20% (19/59), 25.42% (15/59); GST-π expression in postmenopausal ovarian cancer (60.52%) Higher than premenopausal patients (33.33%, P = 0.045); Highly differentiated (G1 ~ G2) ovarian cancer TOPOII resistance expression (80.85%) is higher than the low differentiation (G3) (50.00 %, P=0.028); P-gp expression in the disease progression group was significantly higher than that in the non-progression group (P = 0.027); P-gp, GST-π, TOPO II resistance expression and ovarian cancer tissues Type, surgical pathological stage, ascites cytology and lymph node metastasis have nothing to do. Conclusion The combined detection of P-gp, GST-π and TOPO II expression in ovarian cancer by immunohistochemical method has certain hints for the prediction of clinical chemosensitivity, and may provide a valuable reference for the prognosis.